Questions, answered

PepSense is an AI-powered research and education platform for the peptide science space. You ask a question in plain language and get an evidence-first answer synthesized from the published literature, with every claim linked back to its source. It is built for people who want to understand what the research actually says about a compound, its studied mechanisms, its safety signals, and its regulatory status. It is a reference tool for learning, not a store, a clinic, or a source of personal recommendations.

Ask a question the way you would ask a knowledgeable colleague, and the engine retrieves the most relevant published research, weighs it, and returns a structured answer with inline citations. It draws on a corpus of more than 300,000 published peptide studies plus over 200 individual compound profiles covering mechanism, safety, and regulatory data. Each answer distinguishes the strength of the evidence behind it, so you can see at a glance whether a finding comes from a test tube, an animal model, a human clinical trial, or an FDA-approved label.

The underlying corpus is drawn from peer-reviewed sources: PubMed-indexed journals, published clinical trial records from ClinicalTrials.gov, and the primary scientific literature, alongside curated compound profiles that summarize mechanism, safety, and regulatory information. The platform also tracks FDA regulatory actions as they happen. Answers are source-cited so you can follow any statement back to the study or record it came from and read the original for yourself.

No. PepSense is not a medical service, a telehealth provider, a pharmacy, or a healthcare practice. It does not diagnose conditions, prescribe anything, or provide medical advice tailored to your situation. It is an educational and research reference tool. Questions about your own health belong with a licensed healthcare provider who can account for your individual circumstances.

No. PepSense does not sell, supply, source, or broker any compound, and it is not a vendor or a pharmacy. The platform exists to help you understand the published science and the regulatory landscape. It has no commercial relationship with sellers and does not point you toward places to obtain any substance.

The PCAC is the FDA's Pharmacy Compounding Advisory Committee, a panel that advises the agency on which substances compounding pharmacies should be permitted to work with. On July 23 and 24, 2026, the committee met and voted on whether to recommend seven peptides for addition to the 503A Bulks List, a step toward eventual legal compounding availability; six were recommended and emideltide was not. The seven compounds on that docket are BPC-157, TB-500 (a thymosin beta-4 fragment), KPV, MOTS-c, emideltide, epitalon, and semax. A second batch of five additional compounds is expected to be reviewed around February 2027.

Not on its own. The PCAC vote is advisory and non-binding, and it represents roughly the second of about six steps in the FDA rulemaking process. Even a unanimous recommendation to add a peptide to the 503A Bulks List does not by itself make anything legally compoundable. A realistic timeline from a favorable vote to actual legal compounding availability is at minimum 12 to 18 months, and the FDA can decline to follow the committee's recommendation. PepSense tracks each step so you can see where a given compound stands rather than relying on speculation.

These categories describe how the FDA classifies substances for 503A compounding. Category 1 substances are ones a compounding pharmacy may prepare with a valid prescription. Category 2 substances are ones that may not be compounded, typically because of insufficient safety data or a significant identified concern, and they remain under review. The July 2026 PCAC vote was about whether to move several Category 2 peptides toward Category 1 status; six of the seven were recommended. On the platform you will see status labels such as 'Category 2, under review,' 'Category 2, PCAC July 2026 docket,' 'Category 1 (compoundable with Rx),' 'FDA Approved,' or 'Unscheduled / research-use-only.'

The compound profiles reflect the published literature as it stands, and the platform monitors FDA regulatory actions in real time, so status changes such as advisory committee votes and rulemaking developments are reflected as they occur. Because the regulatory picture around peptides is moving quickly through 2026 and into 2027, the platform is designed to update rather than present a fixed snapshot. Each answer reflects the most current sourced information available at the time you ask.

Your questions are treated as private to your account and are not sold. PepSense is a research tool, and what you look up is your business. The full details of what is collected and how it is handled are laid out in the privacy policy, which is the authoritative reference. If you have specific questions about data handling for your use case, the privacy policy is the place to start.

The Free tier lets you ask questions and get source-cited answers drawn from the research corpus, which covers the core educational use case. Pro is built for people who go deeper: it adds higher usage limits and more advanced research features for those who work with the literature and the regulatory landscape regularly. Both tiers draw on the same evidence-first, fully cited foundation; the difference is depth and volume of use rather than the quality of the sourcing.

No. PepSense is an educational and research reference and is not a substitute for professional medical judgment. It does not account for your medical history, medications, or individual circumstances, and it does not recommend any compound for any person or condition. Any decision that affects your health should be made with a licensed healthcare provider who can evaluate your specific situation. Use the platform to understand what the research says, then bring that understanding to a qualified professional.

General-purpose chatbots generate answers from broad training data and can state things confidently without a verifiable source, sometimes blending outdated or invented details. PepSense is purpose-built for peptide science: it retrieves from a curated corpus of published studies and compound profiles, cites the specific source behind each claim, and clearly labels the strength of the evidence, distinguishing preclinical work from human trials from FDA-approved uses. It also tracks the current regulatory status of each compound, which a general model has no reliable way to keep up to date. The result is an answer you can check rather than one you have to trust blindly.

The platform includes more than 200 compound profiles spanning the peptides most discussed in the research literature. That includes FDA-approved peptide drugs such as semaglutide, tirzepatide, and bremelanotide (PT-141); the compounds currently on the PCAC July 2026 docket, namely BPC-157, TB-500, KPV, MOTS-c, emideltide, epitalon, and semax; and a wide range of other unscheduled, research-use-only peptides such as GHK-Cu, CJC-1295, ipamorelin, and Selank. Each profile summarizes the studied mechanism, the safety signals reported in the literature, and the compound's current regulatory status.